TEL AVIV, Israel, May 28, 2015 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced presentations at two conferences in June.
| Jefferies 2015 Healthcare Conference | |
| Date: | Thursday, June 4 |
| Time: | 8:30am Eastern Time |
| Location: | Grand Hyatt New York |
| Webcast: | http://wsw.com/webcast/jeff88/adhd |
| American Society of Clinical Psychopharmacology | |
| Date: | Monday, June 22 |
| Time: | 2:00pm Eastern Time |
| Location: | Loews Miami Beach Hotel |
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and Fragile X Syndrome. MDX has completed multiple Phase II studies in adults and adolescents with ADHD and has completed a Phase III study in adults with ADHD. The company is conducting a Phase II trial in adolescents and adults with Fragile X Syndrome. For more information please visit the Company’s website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
CONTACT: U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 mrice@lifesciadvisors.com Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 mikebeyer@sambrown.com Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 debbie@alcobra-pharma.com
Help employers find you! Check out all the jobs and post your resume.
